MX2023005678A - Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas. - Google Patents

Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas.

Info

Publication number
MX2023005678A
MX2023005678A MX2023005678A MX2023005678A MX2023005678A MX 2023005678 A MX2023005678 A MX 2023005678A MX 2023005678 A MX2023005678 A MX 2023005678A MX 2023005678 A MX2023005678 A MX 2023005678A MX 2023005678 A MX2023005678 A MX 2023005678A
Authority
MX
Mexico
Prior art keywords
sup
factor receptor
cyclopentathiophen
antagonists
platelet activation
Prior art date
Application number
MX2023005678A
Other languages
English (en)
Spanish (es)
Inventor
Dieter Wiedenmayer
Matthias Eckhardt
Leo Thomas
Juergen Prestle
Marina Kristina Willwacher
Ferenc Kontes
Christofer Siegfried Tautermann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2023005678A publication Critical patent/MX2023005678A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2023005678A 2020-11-16 2021-11-12 Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas. MX2023005678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207719 2020-11-16
PCT/EP2021/081459 WO2022101377A1 (en) 2020-11-16 2021-11-12 Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists

Publications (1)

Publication Number Publication Date
MX2023005678A true MX2023005678A (es) 2023-05-26

Family

ID=73543025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005678A MX2023005678A (es) 2020-11-16 2021-11-12 Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas.

Country Status (19)

Country Link
US (2) US11766443B2 (https=)
EP (1) EP4244229A1 (https=)
JP (2) JP7465368B2 (https=)
KR (1) KR20230109692A (https=)
CN (2) CN116745300A (https=)
AR (1) AR124070A1 (https=)
AU (1) AU2021379248A1 (https=)
CA (1) CA3200710A1 (https=)
CL (2) CL2023001361A1 (https=)
CO (1) CO2023005894A2 (https=)
CR (1) CR20230211A (https=)
DO (1) DOP2023000090A (https=)
EC (1) ECSP23036210A (https=)
IL (1) IL302769A (https=)
JO (1) JOP20230107A1 (https=)
MX (1) MX2023005678A (https=)
PE (1) PE20231855A1 (https=)
SA (1) SA523440809B1 (https=)
WO (1) WO2022101377A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119842821A (zh) * 2025-01-06 2025-04-18 华中科技大学 稳定表达血小板活化因子受体的细胞株、构建方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502392A1 (de) 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
IE870123L (en) * 1986-01-21 1987-07-21 Boehringer Ingelheim Int Thieno-1,4-diazepines
PH30676A (en) 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
DE3909012A1 (de) 1989-03-18 1990-09-20 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen
DE4010528A1 (de) 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
DE4132763A1 (de) 1991-10-02 1993-04-08 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US20050032713A1 (en) * 2002-03-27 2005-02-10 Wurtman Richard J. Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
CA2670031A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors

Also Published As

Publication number Publication date
CN117624188A (zh) 2024-03-01
CR20230211A (es) 2023-07-13
CN116745300A (zh) 2023-09-12
US20220160725A1 (en) 2022-05-26
WO2022101377A1 (en) 2022-05-19
US20230355638A1 (en) 2023-11-09
CO2023005894A2 (es) 2023-05-29
ECSP23036210A (es) 2023-06-30
AR124070A1 (es) 2023-02-08
JP2024099528A (ja) 2024-07-25
KR20230109692A (ko) 2023-07-20
TW202237620A (zh) 2022-10-01
JP7465368B2 (ja) 2024-04-10
US11766443B2 (en) 2023-09-26
JP7810743B2 (ja) 2026-02-03
CA3200710A1 (en) 2022-05-19
AU2021379248A9 (en) 2024-10-10
CL2024000317A1 (es) 2024-07-12
DOP2023000090A (es) 2023-06-15
JOP20230107A1 (ar) 2023-05-16
AU2021379248A1 (en) 2023-06-22
IL302769A (en) 2023-07-01
CL2023001361A1 (es) 2023-11-03
SA523440809B1 (ar) 2024-10-08
JP2023521200A (ja) 2023-05-23
PE20231855A1 (es) 2023-11-21
EP4244229A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
PE20210856A1 (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
JOP20230277A1 (ar) مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز (pi3k) لعلاج الأمراض
JOP20210116A1 (ar) مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها
MX2024001849A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
CO2021002976A2 (es) Amidas heterocíclicas de 5 a 7 miembros como inhibidores de jak
UY38766A (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
EA200870360A1 (ru) Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине
CY1121898T1 (el) Ενωσεις αμιδιου ως αγωνιστες tου υποδοχεα 5-ht4
JP2017524733A5 (https=)
UY38765A (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades
DE60312042D1 (de) Substituierte 1-piperidin-4-yl-4-azetidin-3-yl-piperazinderivate und deren verwendung als neurokininantagonisten
MX2023005678A (es) Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas.
MX2024011914A (es) Derivados de n-(pirrolidin-3-il o piperidin-4-il)acetamida
CO5580823A2 (es) Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf
EA201001326A1 (ru) Стерильные офтальмологические композиции и способ их получения
MX2022012090A (es) Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas del receptor de somatostatina 4 (sstr4).
MX2021016068A (es) Derivados de isoquinolinona como inhibidores de la proteina quinasa rock y usos del mismo.
JOP20230148A1 (ar) مشتقات إيميدازو بيريدين كمثبطات لـ irak4 واستخدامها في علاج أحد الأمراض
MX2023005071A (es) Amidas de isoquinolina enlazadas a n como inhibidores de lrrk2, composiciones farmaceuticas y usos de las mismas.
MX2022013745A (es) Derivados de n-(piperidin-4-il)benzamida de accion luminal.
NZ747797A (en) Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist
NZ747778A (en) Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
HRP20050554B1 (hr) Supstituirani 1- piperidin-3-il-4-piperidin-4-il-piperazinski derivati i njihova primjena kao neurokininskih antagonista
GEAP202416375A (en) Pro drugs of pde10 compounds